KOVARIK, JOHN,SCHMOUDER, ROBERT,BASTIEN, MARIE-CLAUDE,DAVID, OLIVIER,KARLSSON, GOERIL,BOUILLON, THOMAS
申请号：
NZ58961809
公开号：
NZ589618A
申请日:
2009.06.19
申请国别(地区):
NZ
年份:
2012
代理人:
摘要：
Disclosed is the use of a pharmaceutical composition comprising less than 0.5 mg of a 2-amino-2-[2-(4-C2-20 alkylphenyl)ethyl]propane-1,3-diol compound for the treatment, prevention or delay of progression of multiple sclerosis in a patient, wherein the composition is adapted for oral administration and wherein the patient is a paediatric patient such as an infant, child or adolescent. 2-amino-2-[2-(4-C2-20 alkylphenyl)ethyl]propane-1,3-diol compounds include FTY720 (fingolimod) and FTY720 phosphate.
